Dabigatrana |
Inibidor da trombina |
Schulman et al.(1919. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-52. http://dx.doi.org/10.1056/NEJMoa0906598 https://doi.org/10.1056/NEJMoa0906598...
)
|
enoxaparina/dabigatrana 150 mg a cada 12 h |
6 |
dabigatrana (2,4%) vs. varfarina (2,1%) |
SM: dabigatrana (1,6%) vs. varfarina (1,9%) |
Dabigatrana |
Schulman et al.(4746. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033-69, 3069a-3069k.)
|
enoxaparina/dabigatrana 150 mg a cada 12 h |
6 |
dabigatrana (2,3%) vs. varfarina (2,2%) |
SM: dabigatrana (0,3%) vs. varfarina (0,0%) |
Rivaroxabana |
Inibidor do fator Xa |
EINSTEIN Investigators et al.(2121. EINSTEIN Investigators E, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510. http://dx.doi.org/10.1056/NEJMoa1007903 https://doi.org/10.1056/NEJMoa1007903...
)
|
rivaroxabana 15 mg a cada 12 h por 3 semanas; 20 mg/dia |
3, 6 ou 12 |
rivaroxabana (2,1%) vs. varfarina (3,0%) |
SMR: rivaroxabana (8,1%) vs. varfarina (8,1%) |
Rivaroxabana |
EINSTEIN Investigators et al.(2222. EINSTEIN-PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-97. http://dx.doi.org/10.1056/NEJMoa1113572 https://doi.org/10.1056/NEJMoa1113572...
)
|
rivaroxabana 15 mg a cada 12 h por 3 semanas; 20 mg/dia |
3, 6 ou 12 |
rivaroxabana (2,1%) vs. varfarina (1,8%) |
SMR: rivaroxabana (10,3%) vs. varfarina (11,4%) |
Apixabana |
Inibidor do fator Xa |
Agnelli et al.(2323. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. http://dx.doi.org/10.1056/NEJMoa1302507 https://doi.org/10.1056/NEJMoa1302507...
,2424. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708. http://dx.doi.org/10.1056/NEJMoa1207541 https://doi.org/10.1056/NEJMoa1207541...
)
|
apixabana 10 mg a cada 12 h por 7 dias; 5 mg a cada 12 h |
6 |
apixabana (2,3%) vs. varfarina (2,7%) |
SM: apixabana (0,6%) vs. varfarina (1,8%) |
Edoxabana |
Inibidor do fator Xa |
Hokusai-VTE Investigators et al.(2525. Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-15. http://dx.doi.org/10.1056/NEJMoa1306638 https://doi.org/10.1056/NEJMoa1306638...
)
|
heparina baixo peso molecular por 5 dias; edoxabana 60 mg/dia |
3-12 |
edoxabana (3,2%) vs. varfarina (3,5%) |
SMR: edoxabana (8,5%) vs. varfarina (10,3%) |